The absence of a requirement for p53 would also be consistent with clinical studies where p53 status appears to have at best a marginal effect on response and survival to platinum-based treatment of ovarian tumours (Lavarino et al, 2000; Reles et al, 2001). Here, TP53 is linked to ovarian neoplasm.